Amgen R&D chief Sean Harper hits the exits with a one-way ticket to early-stage biotech

Sean Harper is joining the migration out of big biopharma and into the world of emerging biotechs.

The head of R&D at Amgen has turned in his notice, 6 years after taking the senior R&D position vacated by Roger Perlmutter.